PEOPLE ON THE MOVE
Spring Bank
Spring Bank Pharmaceuticals, a Massachusetts company developing biologics for viral infections, has appointed Martin Driscoll as CEO. He replaces Douglas Jensen.
Driscoll recently served as CEO of Asmacure Ltée, a venture-backed clinical-stage biopharmaceutical company. He also headed public pain drug company Javelin Pharmaceuticals until its sale to Hospira.
Spring Bank also elected Kurt Eichler to its board. In the past, he has served as executive VP of LCOR Inc., a real estate company, and as an operating partner at its predecessor, The LinPro Company.